Actively Recruiting
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
Led by Hopital Foch · Updated on 2022-08-03
900
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Lung transplantation often has poorer long-term outcomes compared to other solid organ transplants, with an average survival of six years after the procedure. A major challenge is allograft rejection, which is the leading cause of illness and death in these patients beyond the first year. Researchers are studying the underlying biological mechanisms of transplant dysfunction using blood and tissue samples linked to clinical data to improve early and accurate diagnosis of these complications. This study involves collecting biological samples such as blood, biopsies, and hair from patients with lung disease who require or have undergone lung transplantation. There is no specific treatment or intervention given as part of the study. The focus is on evaluating non-invasive blood markers and gene expression profiles to better understand the risk of rejection and graft loss within the first year after transplant. Participants will be monitored over a period of up to 15 years, during which researchers will assess various biomarkers and gene sets related to transplant dysfunction and response to immunosuppressive treatments. The study also examines patient well-being and the costs associated with different diagnostic strategies. Throughout the study, participants will provide samples and clinical information to help stratify rejection risks and improve transplant outcomes.
CONDITIONS
Brief Title
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women over 15 years of age
- Have a lung condition requiring a transplant planned at Foch Hospital or are being followed up at Foch Hospital after a lung transplant
- Have signed the informed consent form; for patients aged 15 to 18 years, parental consent must also be signed
- Are affiliated with a Health Insurance plan
You will not qualify if you...
- Pregnant, parturient, or lactating women
- Hemoglobin level less than or equal to 8 g/dl
- Adults under legal protection or unable to give consent
- Persons under the protection of justice
- Unable to follow study requirements due to geographical, social, or psychological reasons
- Patient refusal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 years
Participants are observed and biological samples are collected to evaluate non-invasive biomarkers and gene expression profiles related to transplant dysfunction and rejection risk over time.
Periodic visits for sample collection and assessments during the first year and follow-up visits over the long term
Trial Site Locations
Total: 1 location
1
Roux
Suresnes, France
Actively Recruiting
Research Team
A
Antoine ROUX, Dr
E
Elisabeth HULLIER-AMMAR, Dr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here